Search Results - "HUGEN, Patricia W. H"

Assessment of adherence to HIV protease inhibitors: Comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring by HUGEN, Patricia W. H, LANGEBEEK, Nienke, BURGER, David M, ZOMER, Bert, VAN LEUSEN, Rob, SCHUURMAN, Rob, KOOPMANS, Peter P, HEKSTER, Yechiel A

“…Adherence to protease inhibitor-containing antiretroviral therapy is crucial, but difficult to measure. To compare and combine various methods of measuring…”
Get full text

Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients by BAEDE-VAN DIJK, Patricia A, HUGEN, Patricia W. H, VERWEIJ-VAN WISSEN, Corrien P. W. G. M, KOOPMANS, Peter P, BURGER, David M, HEKSTER, Yechiel A

“…To characterize sources of variation in plasma concentrations of nelfinavir and its active metabolite M8 and to evaluate the use of therapeutic drug monitoring…”
Get full text

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations by BURGER, David M, HUGEN, Patricia W. H, AARNOUTSE, Rob E, HOETELMANS, Richard M. W, JAMBROES, Marielle, NIEUWKERK, Pythia T, SCHREIJ, Gerrit, SCHNEIDER, Margriet M. E, VAN DER ENDE, Marchina E, LANGE, Joep M. A

“…The relationship between plasma concentrations of nelfinavir and virologic treatment failure was investigated to determine the minimum effective concentration…”
Get full text

The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy Volunteers by Aarnoutse, Rob E., Grintjes, Karin J. T., Telgt, Denise S. C., Stek, Michael, Hugen, Patricia W. H., Reiss, Peter, Koopmans, Peter P., Hekster, Yechiel A., Burger, David M.

“…Objective This study evaluated the effect of multiple‐dose efavirenz on the steady‐state pharmacokinetics of the combination of indinavir (800 mg) and low‐dose…”
Get full text

Pharmacokinetic Variability Caused by Gender: Do Women Have Higher Indinavir Exposure Than Men? by Burger, David M, Siebers, Marijke C, Hugen, Patricia W. H, Aarnoutse, Rob E, Hekster, Yechiel A, Koopmans, Peter P

“…The pharmacokinetics of HIV-protease inhibitors are characterized by high interpatient variability. Burger et al reviewed indinavir plasma concentrations in…”
Get full text

Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance by HUGEN, Patricia W. H, BURGER, David M, AARNOUTSE, Rob E, BAEDE, Patricia A, NIEUWKERK, Pythia T, KOOPMANS, Peter P, HEKSTER, Yechiel A

“…To determine plasma concentration ratio limits (CORALS) for HIV-protease inhibitors outside of which random plasma concentrations reflect partial compliance or…”
Get full text

Pharmacokinetics of the Protease Inhibitor Indinavir in Human Immunodeficiency Virus Type 1-Infected Children by BURGER, David M, VAN ROSSUM, Annemarie M. C, HUGEN, Patricia W. H, SUUR, Marja H, HARTWIG, Nico G, GEELEN, Sibyl P. M, SCHERPBIER, Henriette J, HOETELMANS, Richard M. W, VULTO, Arnold G, DE GROOT, Ronald

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children by VAN ROSSUM, ANNEMARIE M. C, BERGSHOEFF, ALINA S, FRAAIJ, PIETER L. A, HUGEN, PATRICIA W. H, HARTWIG, NICO G, GEELEN, SIBYL P. M, WOLFS, TOM F. W, WEEMAES, CORRY M. R, DE GROOT, RONALD, BURGER, DAVID M

“…INTRODUCTION.Adherence to highly active antiretroviral therapy is required to obtain an optimal long term virologic response rate of HIV-1-infected children…”
Get full text

No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients by SCHIPPERS, Emile F, HUGEN, Patricia W. H, DEN HARTIGH, Jan, BURGER, David M, HOETELMANS, Richard M. W, VISSER, Leo G, KROON, Frank P

Get full text

Once-daily indinavir plus ritonavir : preliminary results of the PIPO study by BURGER, David M, HUGEN, Patricia W. H, VAN DER ENDE, Marchina E, VAN WIJNGAARDEN, Peter, AARNOUTSE, Rob E, REISS, Peter, LANGE, Joep M. A

“…Triple drug therapy is currently able to provide long-term suppression of viral replication, but toxicity and adherence issues may hamper long-term treatment…”
Get full text

Dose-Finding Study of a Once-Daily Indinavir/Ritonavir Regimen by Hugen, Patricia W. H, Burger, David M, ter Hofstede, Hadewych J. M, Koopmans, Peter P, Stek, Michael, Hekster, Yechiel A, Reiss, Peter, Lange, Joep M.A

“…In antiretroviral therapy, to improve compliance the need is increasing to develop regimens that combine potency and safety with convenient dosing. The…”
Get full text

A retrospective, cohort-based survey of Patients using twice-daily indinavir + ritonavir combinations : Pharmacokinetics, safety, and efficacy by BURGER, David M, HUGEN, Patricia W. H, VAN DER MEER, Jan T. M, REISS, Peter, LANGE, Joep M. A, AARNOUTSE, Rob E, DIELEMAN, Jeanne P, PRINS, Jan M, VAN DER POLL, Tom, TEN VEEN, Jacob H, MULDER, Jan W, MEENHORST, Pieter L, BLOK, Willem L

“…To describe the pharmacokinetics, safety, and efficacy of twice-daily indinavir + ritonavir regimens A cohort-based survey of HIV-infected patients who either…”
Get full text

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study by Nieuwkerk, P T, Sprangers, M A, Burger, D M, Hoetelmans, R M, Hugen, P W, Danner, S A, van Der Ende, M E, Schneider, M M, Schrey, G, Meenhorst, P L, Sprenger, H G, Kauffmann, R H, Jambroes, M, Chesney, M A, de Wolf, F, Lange, J M

“…Adherence to highly active antiretroviral therapy (HAART) for human immunodeficiency syndrome type 1 (HIV-1) infection is essential to sustain viral…”
Get more information

Pros and cons of therapeutic drug monitoring of antiretroviral agents by Burger, David M, Aarnoutse, Rob E, Hugen, Patricia W.H

“…Therapeutic drug monitoring has the promise to become a part of routine patient care in the treatment of HIV infection. It is known that plasma drug…”
Get full text

Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy by Burger, D M, Hoetelmans, R M, Hugen, P W, Mulder, J W, Meenhorst, P L, Koopmans, P P, Brinkman, K, Keuter, M, Dolmans, W, Hekster, Y A

“…All human immunodeficiency virus type 1 (HIV-1)-infected patients who started to use indinavir (800 mg three times a day) as part of their triple drug regimen…”
Get more information

Carbamazepine--indinavir interaction causes antiretroviral therapy failure by Hugen, PW, Burger, DM, Brinkman, K, ter Hofstede, HJ, Schuurman, R, Koopmans, PP, Hekster, YA

“…OBJECTIVE: To report a case of antiretroviral therapy failure caused by an interaction between carbamazepine and indinavir. CASE SUMMARY: A 48-year-old…”
Get full text

Authors' Reply by Hugen, Patricia WH, Burger, David M

Get full text

Author's Reply by Hugen, Patricia WH, Burger, David M

“…Abstract only…”
Get full text

Authors' Reply by Hugen, Patricia WH, Burger, David M

Get full text

Assessment of Adherence to HIV Protease Inhibitors: Comparison and Combination of Various Methods, Including MEMS (Electronic Monitoring), Patient and Nurse Report, and Therapeutic Drug Monitoring by Hugen, Patricia W. H, Langebeek, Nienke, Burger, David M, Zomer, Bert, van Leusen, Rob, Schuurman, Rob, Koopmans, Peter P, Hekster, Yechiel A

“…BACKGROUND:Adherence to protease inhibitor-containing antiretroviral therapy is crucial, but difficult to measure. OBJECTIVE:To compare and combine various…”
Get full text